CAR

Biotech Stocks Lose Momentum with Greece Crisis; Blockbuster Immunotherapy Deal

Biotech Stocks in Broad Sell-Off
The biotech sector is usually immune to macro events but today the crisis in Greece gave investors an excuse to take profits. Many biotech stocks and ETFs were down over 3% faring worse than the NASDAQ down 2.4%. The sector, as tracked by IBB, is still up 18.87% YTD after hitting a high of 383 on […]

These Promising Cancer Therapies Are a Biotech Stocks "Triple Play"

These Promising Cancer Therapies Are a Biotech Stocks “Triple Play”Companies / BioTechJun 19, 2015 – 03:04 PM GMTBy: Money_MorningErnie Tremblay writes: On Jan. 7, 2015, CytRX Corp. (NASDAQ: CYTR) announced positive results from a study of its experimental brain cancer drug, aldoxorubicin, and the company’s stock immediately jumped 15.8%. Then, over the next four months, it nearly doubled.Over the months […]

Biotech Bull Market: Trends to Watch in 2015… #3

Biotech Sector Moves Up In Tiny Steps
Risk Remains On
AACR Next Week Will Move Cancer Stocks
Biotech indices and ETFs are trying to hit new highs but momentum is easing and trading is choppy. Nonetheless we are moving up from the brief correction near channel lows at the end of Q1. Sentiment remains strong.
Here is a review of the Five Trends we […]

3 Stocks With 100% Upside

Biotech stocks had a banner year in 2014. Agios Pharmaceuticals, Inc. (Nasdaq: AGIO ), Avanir Pharmaceuticals, Inc. (Nasdaq: AVNR ) and OvaScience, Inc. (Nasdaq: OVAS ), for example, each rose roughly 400%.Indeed, each year brings another set of home run stock picks in this sector, thanks to the twin pillars of FDA approval and promising clinical trial results.Trying to handicap […]

The Lone Biotech Bear?

Judging from the atmosphere at last week’s JP Morgan Healthcare conference in San Francisco – which industry veteran and long-time participant Henri Termeer described as the “most optimistic” he had every experienced – the industry’s well-documented problems are clearly behind us. After a decade in the doldrums, the biotech market is on a bull run stretching back more than a […]